UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 7, 2021
APPLIED UV, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-39480 | 84-4373308 | ||
(State or other jurisdiction of | (Commission | (IRS Employer | ||
incorporation) | File Number) | Identification No.) |
150 N. Macquesten Parkway Mount Vernon, NY |
10550 | |
(Address of principal executive offices) | (Zip Code) |
(914) 665-6100
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name
of each exchange
on which registered |
||
Common Stock, par value $0.0001 per share | AUVI | The Nasdaq Stock Market LLC | ||
10.5% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share | AUVIP | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1 |
Item 1.01. Entry into a Material Definitive Agreement.
The disclosures set forth in Item 5.02(c) below are incorporated by reference into this Item 1.01.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) Resignation of Principal Executive Officer or Director
On December 7, 2021, Keyoumars Saeed, the Chief Executive Officer and a Director of the Board of Directors (the “Board”) of Applied UV, Inc. (the “Company”) and the Chief Executive Officer of SteriLumen, Inc., a wholly owned subsidiary of the Company (“SteriLumen”), resigned effective immediately. Mr. Saeed’s resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
(c) Appointment of Principal Executive Officer Director
The Board has appointed James Alecxih, age 57, as the Company’s Chief Executive Officer of the Company, and Director of the Board, pursuant to an two (2) year Employment Agreement dated December 9, 2021 between the Company and Mr. Alecxih (the “Employment Agreement”). The term of the Company’s directors, including Mr. Alecxih, expires at the annual meeting of stockholders to be held in 2022 or upon the election and qualification of successor directors. Mr. Alecxih was also appointed a President of SteriLumen.
The Employment Agreement provides Mr. Alecxih with: (i) a base salary of $400,000 per year, (ii) following the end of each calendar year beginning with the 2022 calendar year, an annual discretionary performance bonus targeted of up to 125% of the Mr. Alecxih’s base salary (the “Target Bonus”), based upon periodic assessments of Mr. Alecxih’s performance as well as the achievement of specific individual and corporate objectives determined by the Board or a committee thereof after consultation with Mr. Alecxih and provided to Mr. Alecxih in writing no later than the end of the first calendar quarter of the applicable bonus year. Under the terms of the Employment Agreement, Mr. Alecxih will also receive (i) 75,000 shares of restricted common stock of the Company and (ii) a ten (10) year option to purchase 175,000 shares of common stock of the Company, at a per share price equal to the fair market value on the effective date of the Employment Agreement (collectively, the “Equity Awards”). The Equity Awards shall be subject to a quarterly vesting schedule and vest evenly over a three (3) year period, commencing on the effective date of the Employment Agreement. No portion of the Equity Awards shall be vested on the effective date of the Employment Agreement. Any options granted by the Company to Mr. Alecxih that have vested shall terminate and not be exercisable ninety (90) days after his termination. Mr. Alecxih is entitled to four (4) weeks’ vacation time during each year and other benefits as described in the Employment Agreement. The foregoing summary does not purport to be complete and is qualified in its entirety by the Employment Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Mr. Alecxih brings 35 years of experience in the medical device industry and has helped, through a variety of positions, bring innovative medical device technologies to market. From 2020 to 2021 Mr. Alecxih was the Chief Executive Officer of ViveBio Scientific, which manufactures and sells both lateral and vertical flow blood storage devices that allow samples to be shipped to laboratories without the need for temperature control. From 2018 to 2020, Mr. Alecxih served as the Chief Commercial Officer for Viewray, Inc where he established a commercial strategy for market adoption of the MRIdian system. From 2015 to 2016 Mr. Alecxih served as the Chief Executive Officer for Free Air Inc., the manufacturer of an ULPA grade, portable, personal respirator that was designed to allow free movement in environments with extreme air pollution or highly contagious environments such as pandemics. From 2000 to 2015 Mr. Alecxih worked for Intuitive Surgical, Inc. and was ultimately Senior Vice President, North America, South America, Australia & New Zealand. At Intuitive, Mr. Alecxih helped introduce the da Vinci Surgical System. During his 15 years at Intuitive the company grew from first revenue to over $1.8B in sales and successfully introduced four new robotic models and multiple surgical applications. Mr. Alecxih currently serves on the board of ViveBio Scientific and Athroba. He holds a Bachelor of Arts degree in Business from Le Tourneau University in, Longview Texas.
(d) Appointment of New Director
The disclosures set forth in Item 5.02(c) above are incorporated by reference into this Item 5.02(d).
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description |
10.1 | Employment Agreement between the Company and James Alecxih, dated December 1, 2021 |
99.1 | Press Release |
2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
APPLIED UV, INC. | |
Date: December 9, 2021 | By: /s/ Max Munn |
Name: Max Munn | |
Title: President |
3 |
EMPLOYMENT AGREEMENT
This Employment Agreement (the “Agreement”) dated as of the 9th day of December, 2021 (the “Effective Date”) is between Applied UV, Inc., a Delaware corporation (the “Company”), and James Alecxih, an individual residing at 3780 N. Berkeley Lake Road, Duluth, GA 30096 (“Executive”).
W I T N E S S E T H:
A. The Company desires to hire Executive as a Chief Executive Officer and Executive desires to accept such employment.
B. The Company and Executive desire to set forth in this Agreement the terms, conditions and obligations of the parties with respect to such employment, and this Agreement is intended by the parties to supersede all previous understandings, whether written or oral, concerning such employment.
NOW, THEREFORE, for and in consideration of the premises and the mutual covenants contained herein, the parties agree as follows:
1. Employment. The Company hereby employs Executive as the Chief Executive Officer of the Company and President of SteriLumen, Inc., a wholly-owned subsidiary of the Company and Executive hereby accepts such employment, subject to the terms and conditions hereof. During the Term of Employment, the Executive shall be responsible for the performance of those duties consistent with the Executive’s position as Chief Executive Officer of the Company. The Executive shall serve upon, and report to, the Company’s Board of Directors (the “Board”) and shall perform and discharge faithfully, diligently, and to the best of the Executive’s ability, the Executive’s duties and responsibilities hereunder and under the Bylaws of the Company. The Executive’s continued service on the Board shall be subject to, along with the other members of the Board, the election of shareholders at the company’s annual meetings. Any termination of the Executive pursuant to Section 7, shall constitute an automatic resignation from the Board. Additionally, Executive shall perform services and hold positions at other Affiliates (as defined in Section 5) as directed by the Board. It is acknowledged that Executive may, from time to time, serve on Boards of business entities that are not affiliated with the Company, which entities do not compete with the Company and where the role of participation is in a non-executive role. Except for such Board service (and the personal endeavors described below), Executive shall not, without the written approval of the Company, render services of a business or commercial nature on his own behalf or on behalf of any person, firm, or corporation, for compensation that will interfere with his performance of duties hereunder. .
2. Location. As may be necessary to perform Executive’s duties hereunder from time to time, the Executive shall work out of such office as the Company may establish in the Greater Atlanta Metropolitan Area. Executive shall travel as reasonably required by the Executive’s job duties.
3. Term. The Term of this Agreement is two (2) years commencing on the Effective Date and ending on the second anniversary of the Effective Date and shall be automatically extended for an additional consecutive two (2) year period on the second (2nd) anniversary of the Effective Date and each subsequent two (2) year anniversary thereof, unless and until the Company or Executive provides written notice to the other party not less than one hundred and eighty (180) days before such anniversary date that such party is electing not to extend the Term, in which case the Term shall end at the expiration of the Term as last extended, unless sooner terminated as set forth in Section 7.
4. Compensation; Benefits.
(a) Salary. During the Term of this Agreement, the Company agrees to pay Executive an annual salary of $400,000 (the “Salary”). The Salary shall be payable in accordance with the Company’s regular payroll schedule and will be subject to payroll taxes and other customary payroll deductions.
(b) Annual Discretionary Bonus: Following the end of each calendar year beginning with the 2022 calendar year, the Executive will be eligible to receive an annual performance bonus targeted of up to 125% of the Executive’s Base Salary (the “Target Bonus”), based upon periodic assessments of the Executive’s performance as well as the achievement of specific individual and corporate objectives determined by the Board or a committee thereof after consultation with the Executive and provided to the Executive in writing no later than the end of the first calendar quarter of the applicable bonus year. The Target Bonus must be approved by the Audit and Compensation Committee. Except as specified in Paragraph 8(b) below, no amount of annual bonus is guaranteed, and with the exception of the circumstances described in Paragraph 8(b) below, the Executive must be an employee on December 31 of the applicable bonus year in order to be eligible for any annual bonus for such year. Any bonus will be paid no later than March 15 of the calendar year following the calendar year to which the bonus relates.
(c) Equity Awards. Effective as of the Effective Date, the Board or a committee thereof shall grant the Executive (i) 75,000 shares of restricted common stock of the Company and (ii) a ten (10) year option to purchase 175,000 shares of common stock of the Company, at a per share price equal to the fair market value on the Effective Date (collectively, the “Equity Awards”). The Equity Awards shall be subject to a quarterly vesting schedule and vest evenly over a three (3) year period, commencing on the Effective Date. No portion of the Equity Awards shall be vested on the Effective Date. Any options granted by the Company to the Executive that have vested shall terminate and not be exercisable ninety (90) days after of the termination of the Executive.
(d) Other Benefits. During the Term of Executive’s employment, Executive shall be entitled to participate the Company-funded healthcare insurance plan and in all other benefits, perquisites, vacation days, benefit plans or programs of the Company which are available generally to office employees and other employees of the Company in accordance with the terms of such plans, benefits or programs. Company will pay Executive’s portions of benefit plan. During the Term, the employee will be entitled to four (4) weeks’ vacation time during each year.
(e) Expenses. Executive shall be reimbursed for Executive’s reasonable and approved expenses related to and for promoting the business of the Company, including expenses for travel and similar items that arise out of Executive’s performance of services under this Agreement.
5. Extent of Service. The Executive agrees to devote his business time, loyalty, attention, skill and efforts to the faithful performance and discharge of his duties and responsibilities as Chief Executive Officer of the Company in conformity with professional standards and in a manner consistent with the obligations imposed under applicable law. The Executive shall promote the interests of the Company and each other company or other organization which is controlled directly or indirectly by the Company (each an “Affiliate” and collectively the “Affiliates”) in carrying out the Executive’s duties and responsibilities. The Executive may serve on the board of directors of other companies, which service shall not interfere with the performance of Executive’s duties hereunder.
6. Covenants Regarding Confidential Information and Other Matters. All payments and benefits to Executive under the Agreement shall be subject to Executive’s compliance with the provisions of this Section 6. For purposes of this Section 6, the term “Company” shall mean, Applied UV, Inc. and any direct or indirect wholly or majority owned subsidiary of the Company.
(a) Confidential Information; Inventions. (i) The Executive shall not disclose or use at any time, either during the Term of this Agreement or thereafter, any Confidential Information (as defined below) of which the Executive is or becomes aware, whether or not such information is developed by him, except to the extent that such disclosure or use is directly related to and required by the Executive’s performance in good faith of duties for the Company. The Executive will take all appropriate steps to safeguard Confidential Information in his possession and to protect it against disclosure, misuse, espionage, loss and theft. The Executive shall deliver to the Company at the end of the Term, or at any time the Company may request, all memoranda, notes, plans, records, reports, computer tapes and software and other documents and data (and copies thereof) relating to the Confidential Information or the Work Product (as hereinafter defined) of the business of the Company which the Executive may then possess or have under his control. Notwithstanding the foregoing, the Executive may truthfully respond to a lawful and valid subpoena or other legal process, but shall give the Company the earliest possible notice thereof, shall, as much in advance of the return date as possible, make available to the Company and its counsel the documents and other information sought, and shall assist the Company and such counsel in resisting or otherwise responding to such process.
(ii) As used in this Agreement, the term “Confidential Information” means information that is not generally known to the public and that is used, developed or obtained by the Company in connection with its business, including, but not limited to, information, observations and data obtained by the Executive while employed by the Company or any predecessors thereof (including those obtained prior to the Effective Date) concerning (i) the business or affairs of the Company (or such predecessors), (ii) products or services, (iii) fees, costs and pricing structures, (iv) designs, (v) analyses, (vi) drawings, photographs and reports, (vii) computer software, including operating systems, applications and program listings, (viii) flow charts, manuals and documentation, (ix) data bases, (x) accounting and business methods, (xi) inventions, devices, new developments, methods and processes, whether patentable or unpatentable and whether or not reduced to practice, (xii) customers and clients and customer or client lists, (xiii) other copyrightable works, (xiv) all production methods, processes, technology and trade secrets, and (xv) all similar and related information in whatever form. Confidential Information will not include any information that has been published (other than through a disclosure by the Executive in breach of this Agreement) in a form generally available to the public prior to the date the Executive proposes to disclose or use such information. Confidential Information will not be deemed to have been published merely because individual portions of the information have been separately published, but only if all material features comprising such information have been published in combination.
(iii) As used in this Agreement, the term “Work Product” means all inventions, innovations, improvements, technical information, systems, software developments, methods, designs, analyses, drawings, reports, service marks, trademarks, trade names, logos and all similar or related information (whether patentable or unpatentable, copyrightable, registerable as a trademark, reduced to writing, or otherwise) which relates to the Company’s actual or anticipated business, research and development or existing or future products or services and which are conceived, developed or made by the Executive (whether or not during usual business hours, whether or not by the use of the facilities of the Company, and whether or not alone or in conjunction with any other person) while employed by the Company (including those conceived, developed or made prior to the Effective Date) together with all patent applications, letters patent, trademark, trade name and service mark applications or registrations, copyrights and reissues thereof that may be granted for or upon any of the foregoing. All Work Product that the Executive may have discovered, invented or originated during his employment by the Company prior to the Effective Date, or that he may discover, invent or originate during the Period of Employment, shall be the exclusive property of the Company, as applicable, and Executive hereby assigns all of Executive’s right, title and interest in and to such Work Product to the Company, including all intellectual property rights therein. Executive shall promptly disclose all Work Product to the Company, shall execute at the request of the Company any assignments or other documents the Company may deem necessary to protect or perfect its rights therein, and shall assist the Company, at the Company’s expense, in obtaining, defending and enforcing the Company’s rights therein. The Executive hereby appoints the Company as his attorney-in-fact to execute on his behalf any assignments or other documents deemed necessary by the Company to protect or perfect the Company, the Company’s rights to any Work Product. As used herein Work Product does not include purely personnel endeavors (such as writing a book on unrelated business ventures and/or the development of business concepts unrelated to the business of the Company) and the Company makes no claim of any rights to such activities.
(b) Restriction on Competition. Executive agrees that if the Executive were to become employed by, or substantially involved in, the business of a competitor that manufactures or distributes products that compete directly with the products of the Company (“Restricted Competitor) during the Restricted Period (defined below), it would be very difficult for the Executive not to rely on or use the Company’s trade secrets and confidential information. Thus, to avoid the inevitable disclosure of the Company’s trade secrets and confidential information, and to protect such trade secrets and confidential information and the Company’s relationships and goodwill with customers, during the Restricted Period, the Executive will not directly or indirectly through any other Person engage in, enter the employ of, render any services to, have any ownership interest in, nor participate in the financing, operation, management or control of, any Restricted Competitor of the Company in the United States or globally.
(c) Non-Solicitation of Clients by Executive. Executive agrees that for so long as Executive is employed by the Company and continuing for one (1) year thereafter (such period is referred to as the “Restricted Period”) Executive shall not solicit or attempt to solicit the business of any customers or clients of the Company with respect to services that the Company performs for such customers or clients regardless of how or when the Executive first obtained business from or provided services to such customers or clients.
(d) Non-Solicitation of Employees. Executive agrees that during the Restricted Period not to directly or indirectly, by sole action or in concert with others, induce or influence, or seek to induce or influence any person who is currently engaged by the Company at the time of the termination of Executive’s employment as an employee, agent, independent contractor, or otherwise to leave the employ of the Company or any successor or assign, or to hire any such person.
(e) Non-Disparagement. During Executive’s employment with the Company and at any time thereafter, Executive shall not, directly or indirectly, engage in any conduct or make any statement, whether in commercial or noncommercial speech, disparaging or criticizing in any way the Company, or any of their respective officers, directors, employees, customers or agents or any products or services offered by any of them, nor shall Executive engage in any other conduct or make any other statement that could be reasonably expected to impair the goodwill of any of them.
(f) Understanding of Covenants. The Executive acknowledges that, in the course of his employment with the Company, he has become familiar, or will become familiar, with the Company’s trade secrets and with other confidential and proprietary information concerning the Company and that his services have been and will be of special, unique and extraordinary value to the Company. The Executive agrees that the foregoing covenants set forth in this Section 6 (together, the “Restrictive Covenants”) are reasonable and necessary to protect the Company’s trade secrets and other confidential and proprietary information, good will, stable workforce, and customer relations.
Without limiting the generality of the Executive’s agreement in the preceding paragraph, the Executive (i) represents that he is familiar with and has carefully considered the Restrictive Covenants, (ii) represents that he is fully aware of his obligations hereunder, (iii) agrees to the reasonableness of the length of time, scope and geographic coverage, as applicable, of the Restrictive Covenants, (iv) agrees that the Company currently conducts business throughout the continental United States and the rest of the world, and (v) agrees that the Restrictive Covenants will continue in effect for the applicable periods set forth above in this Section 6 regardless of whether the Executive is then entitled to receive severance pay or benefits from the Company. The Executive understands that the Restrictive Covenants may limit his ability to earn a livelihood in a business similar to the business of the Company, but he nevertheless believes that he has received and will receive sufficient consideration and other benefits as an employee of the Company and as otherwise provided hereunder or as described in the recitals hereto to clearly justify such restrictions which, in any event (given his education, skills and ability), the Executive does not believe would prevent him from otherwise earning a living. The Executive agrees that the Restrictive Covenants do not confer a benefit upon the Company disproportionate to the detriment of the Executive.
(g) Remedies for Breach of Covenants. (i) In the event that a Restrictive Covenant shall be deemed by any court to be unreasonably broad in any respect, it shall be modified in order to make it reasonable and shall be enforced accordingly; provided, however, that in the event that any court shall refuse to enforce any of the Restrictive Covenants, then the unenforceable covenant shall be deemed eliminated from the provisions of this Agreement for the purpose of those proceedings to the extent necessary to permit the remaining covenants to be enforced so that the validity, legality or enforceability of the remaining provisions of this Section 6 shall not be affected thereby.
(ii) Executive acknowledges that any breach of the Restrictive Covenants may cause irreparable harm to the Company which will be difficult if not impossible to ascertain, and the Company shall be entitled to seek equitable relief, including injunctive relief, against any actual or threatened breach hereof, without bond and without liability should such relief be denied, modified or vacated. Neither the right to obtain such relief nor the obtaining of such relief shall be exclusive of or preclude the Company from any other remedy the Company or may have hereunder or at law or equity.
7. Termination. This Agreement and the employment of the Executive shall terminate upon the occurrence of the following events.
(a) Death or Disability. This Agreement and the employment of the Executive shall terminate upon the death or of the Executive of the finding by the Company’s Board of Directors that the Executive has a Disability. “Disability” means a physical or mental impairment, which as reasonably determined by the Board, prevents the Executive from performing the essential functions of the Executive’s position for a period of more than any three (3) months in any six (6)-month period.
(b) Termination by the Company. This Agreement and the employment of the Executive shall terminate at the election of the Company, with or without “Cause” (as defined below), immediately upon written notice by the Company to the Executive. “Cause” means for purposes of this Section 7: Any of the following acts that are committed by the Executive (1) continued willful failure, as determined in the reasonable good faith discretion of the Board, to perform the Executive’s assigned duties or responsibilities as directed or assigned by the Board (other than due to death or Disability) after written notice thereof from the Board describing in reasonable detail the failure to perform and providing the Executive a reasonable opportunity to address such alleged failure; (2) being convicted of, or entering a plea of nolo contendere to a felony or committing any act of moral turpitude, dishonesty or fraud against the Company or its Affiliates; (3) intentional damage to the Company’s assets or reputation caused by the Executive; (4) breach by the Executive of Sections 6 or 10(a)(iv) of this Agreement; (5) intentional engagement by the Executive in any competitive activity which would constitute a breach of the Executive’s duty of loyalty to the Company; or (6) willful conduct by the Executive that is demonstrably and materially injurious to company, monetarily or otherwise. Failure to meet performance standards or objectives, by itself, does not constitute “Cause.” No finding of Cause shall be effective unless and until the Board votes to terminate the Executive’s employment for Cause at a Board meeting or by unanimous written consent.
(c) Termination by the Executive. This Agreement and the employment of the Executive shall terminate at the election of the Executive, with or without “Good Reason” (as defined below), upon written notice by the Executive to the Company (subject, if it is with Good Reason, to the timing provisions set forth in the definition of Good Reason); provided that if the termination is without Good Reason, the Executive will provide ninety (90) days written notice to the Company.
“Good Reason” means (without the Executive’s consent) (i) a material diminution of the Executive’s base compensation; (ii) a material diminution in the Executive’s duties, authority or responsibilities, including without limitation, a material change in the Executive’s reporting responsibilities such that the Executive no longer reports directly to the Board or any successor to the Company’s Board, ; (iii) the Company’s requiring the Executive to relocate the Executive’s primary office more than sixty (60) miles from the Executive’s then current primary office; (iv.) any acquirer, successor or assign of the Company fails to assume and perform, in all material respects, the obligations of the Company hereunder.
provided, however, that in each case, the Company shall have a period of not less than thirty (30) days to cure any act constituting Good Reason following the Executive’s delivery to the Company of written notice within ninety (90) days of the action or omission constituting Good Reason and the Executive shall actually terminate the Executive’s employment within thirty (30) days following the expiration of the Company’s cure period if the Company has not cured.]
8. Effect of Termination.
(a) All Terminations Other Than by the Company Without Cause or by the Executive With Good Reason . If the Executive’s employment is terminated under any circumstances other than a termination by the Company without Cause or a termination by the Executive with Good Reason (including a voluntary termination by the Executive without Good Reason or a termination by the Company for Cause or due to the Executive’s death or Disability), the Company’s obligations under this Agreement shall immediately cease and the Executive shall only be entitled to receive (i) the Salary that has accrued and is unpaid and to which the Executive is entitled as of the effective date of such termination and to the extent consistent with general Company policy, to be paid in accordance with the Company’s established payroll procedure and applicable law but no later than the next regularly scheduled pay period, (ii) unreimbursed business expenses for which expenses the Executive has timely submitted appropriate documentation, and (iii) any bonus earned and approved by the Board but not yet paid; (iv) any amounts or benefits to which the Executive is then entitled under the terms of the benefit plans then-sponsored by the Company in accordance with their terms (and not accelerated to the extent acceleration does not satisfy Section 409A of the Internal Revenue Code of 1986, as amended, (the “Code”)) (the payments described in this sentence, the “Accrued Obligations”).
(b) Termination by the Company Without Cause or by the Executive With Good Reason. If the Executive’s employment is terminated by the Company without Cause or by the Executive with Good Reason, the Executive shall be entitled to the Accrued Obligations. In addition, the Company shall: (i) continue to pay to the Executive, in accordance with the Company’s regularly established payroll procedures, the Executive’s Base Salary for a period of twelve (12) months; (ii) pay to the Executive, in a single lump sum on the Payment Date (as defined below) an amount in cash equal to the pro-rated amount of any the Target Bonus for the year in which Executive is terminated and (iii) continue Employee’s health benefit under COBRA for a maximum of 12 months or until such time the Executive qualifies for health benefits from a new employer, whichever is less (collectively, the “Severance Benefits”).
(c) Release. As a condition of the Executive’s receipt of the Severance Benefits, the Executive must execute and deliver to the Company a severance and release of claims agreement in a reasonable form to be provided by the Company (which shall include a release of all releasable claims, reaffirmation of continuing obligations, and confidentiality and reasonable cooperation obligations, but shall not expand the Executive’s then-existing restrictive covenants or impose restrictive covenant obligations on the Executive that do not then exist) (the “Severance Agreement”), which Severance Agreement must become irrevocable within sixty (60) days following the date of the Executive’s termination of employment (or such shorter period as may be directed by the Company). The Severance Benefits will be paid or commence to be paid in the first regular payroll beginning after the Severance Agreement becomes effective, provided that if the foregoing sixty (60) day period would end in a calendar year subsequent to the year in which the Executive’s employment ends, the Severance Benefits will not be paid or begin to be paid before the first payroll of the subsequent calendar year (the date the Severance Benefits commence pursuant to this sentence, the “Payment Date”). The Executive must not materially breach the Confidentiality Agreement or the Severance Agreement in order to be eligible to receive or continue receiving the Severance Benefits.
9. Withholding of Taxes. The Company may withhold from any benefits payable under the Agreement all federal, state, city or other taxes as shall be required pursuant to any law or governmental regulation or ruling.
10. Executive’s Representations and Understandings.
(a) Executive represents and warrants to the Company that (i) Executive is free to enter into this Agreement, (ii) this Agreement and Executive’s obligations hereunder do not violate the terms of any other agreement to which Executive is a party or by which Executive is bound,(iii) Executive is not subject to any confidentiality agreement, non-competition agreement, non-solicitation agreement or any other similar agreement that restricts Executive’s ability to perform the services for the Company for which Executive was hired and (iv) other than as has been expressly disclosed to the Company by the Executive, the Executive has not been (1) arrested or indicted for a felony crime, a misdemeanor crime involving fraud, dishonesty or illegal drug possession; (2) the subject of a formal complaint filed by a co-worker with a former employer involving sexual harassment or other abusive behavior or (3) during the last ten (10) years been involved as the subject of any of the events described in Item 401 (f) of Regulation S-K under the Securities Act of 1933, as amended. The Executive understands and acknowledges that the Company is a publicly traded company subject to the rules and regulations of the Securities and Exchange Commission and The NASDAQ Stock Market LLC and as such its Chief Executive Officer’s background is important to the Company’s continued good standing with these regulators, the representations contained in clause (iv) of this Section 10(a) are consistent with the Company’s efforts to maintain such good standing and any breach of clause (iv) would cause the Company material harm.
(b) Executive understands and agrees to comply with all of the written rules and procedures governing employment with the Company, and any direct or indirect wholly or majority owned subsidiary of the Company, including but not limited to the Company’s Executive Handbook, written supervisory procedures, and any other employment, compliance, and/or supervisory documents the Company issues from time to time.
11. Severability. If any provision of this Agreement, as applied to any party or to any circumstance, shall be found by a court to be void, invalid or unenforceable, the same shall in no way affect any other provision of this Agreement or the application of any such provision in any other circumstance, or the validity or enforceability of this Agreement.
12. Entire Understanding. This Agreement contains the entire understanding of the parties hereto relating to the subject matter contained herein and supersedes all prior and collateral agreements, understandings, statements and negotiations of the parties. Each party acknowledges that no representations, inducements, promises or agreements, oral or written, with reference to the subject matter hereof have been made other than as expressly set forth herein. This Agreement may not be modified or rescinded except by a written agreement signed by both parties.
13. Notices. All notices under this Agreement shall be in writing and shall be (a) delivered in person, (b) sent by e-mail, or (c) mailed, postage prepaid, either by registered or certified mail, return receipt requested, or overnight express carrier, addressed in each case as set forth on the signature page hereto (or such other address as may be designated by the party by giving notice in accordance with this Section. All notices sent pursuant to the terms of this Section shall be deemed received (i) if personally delivered, then on the date of delivery; (ii) if sent by e-mail before 2:00 p.m. local time of the recipient, on the day sent if a business day or if such day is not a business day or if sent after 2:00 p.m. local time of the recipient, then on the next business day; (iii) if sent by overnight, express carrier, on the next business day immediately following the day sent; or (iv) if sent by registered or certified mail, on the earlier of the third business day following the day sent or when actually received.
14. Consideration. Executive acknowledges that Executive’s continued employment during the term of this Agreement and the other compensation and benefits provided in this Agreement are sufficient compensation and consideration for purposes of entering into the restrictions and limitations provided herein, including, but not limited to, the restrictions and limitations set forth in Section 6.
15. Waiver. Failure by either party to insist upon strict compliance with any of the terms, covenants or conditions hereof shall not be deemed a waiver of such term, covenant or condition, nor shall any waiver or relinquishment of any right or remedy hereunder at any time be deemed a waiver or relinquishment of such right or remedy.
16. Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be governed by and construed in accordance with the laws of the State of Georgia applicable to contracts made and to be performed therein.
17. No Presumption. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting or causing any instrument to be drafted.
18. Counterparts. This Agreement may be executed in multiple counterparts, all of which together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the parties have executed this Employment Agreement as of the day and year first above written.
EXECUTIVE | |
______________________________ James Alecxih |
|
APPLIED UV, INC.
By: Name: Max Munn Title: President |
Applied UV Announces the Appointment of James Alecxih as Chief Executive Officer
Highly Accomplished Executive with Proven Track Record of Leading Healthcare Businesses
Q Saeed to transition to consultant to the Company
Mount Vernon, NY // December 9, 2021 – Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), an industry leader in air and surface pathogen elimination technology today announced that its Board of Directors has appointed James Alecxih as Chief Executive Officer and as a member of the Company’s Board of Directors, effective December 8, 2021. Mr. Alecxih’s appointment follows the resignation of Keyoumars (“Q”) Saeed, who served as Chief Executive Officer since June 30, 2020, prior to the Company’s initial public offering (“IPO”) on August 31, 2020. Mr. Saeed will serve as a consultant to the Company for up to six months, with a primary focus on evaluating potential synergistic acquisitions.
During his leadership of Applied UV, Mr. Saeed was instrumental in leading the Company’s successful Nasdaq IPO, strengthening the senior management team, formulating a commercial development strategy and building a global reseller and distributor infrastructure. Mr. Saeed also led the formation of a digital marketing strategy to launch a DTC consumer channel. While at Applied UV, Mr. Saeed successfully executed a secondary equity offering and a preferred offering to support the Company’s growth strategy and to fund three accretive acquisitions in the disinfection space.
Max Munn, Founder and President of Sterilumen, said, "On behalf of the Applied UV Board of Directors, I would like to thank Q Saeed for his outstanding service as Chief Executive Officer. Under his leadership, the company made meaningful progress on a series of important initiatives, including executing a capital formation strategy to enable the significant acquisition activity and associated integration, advancing our operational objectives, and setting the company up for long term success and value creation. We appreciate Q’s contributions and wish him well.”
Commenting
on the appointment of James Alecxih as chief executive officer, Joel Kanter, Non-Executive Chairman of the Board, said, “Applied
UV’s Board of Directors is excited to appoint Jim as our CEO. After a comprehensive search and careful consideration, our Board
unanimously concluded that Jim has the right mix of skills, experience and talent to lead Applied UV to achieve its full potential. Jim
has deep experience in global sales and distribution of medical devices and technology. Further, he has a strong track record of managing
global sales for healthcare businesses and partnering with healthcare professionals, which will be critical to Applied UV as we continue
to execute our growth strategy, accelerate innovation and advance our pathogen elimination portfolio of products.”
"I would like to thank the Board of Directors for placing their trust and confidence in me,” stated James Alecxih. “It
is truly an honor to serve as the next Chief Executive Officer of Applied UV. I firmly believe that Applied UV is well positioned
to serve our customers by bringing comprehensive solutions globally. I look forward to working with the dedicated employees in
driving growth in this attractive market and building on our position as a recognized market leader in the pathogen elimination and air
purification industry."
Prior to joining Applied UV, Mr. Alecxih was President and Chief Executive Officer of Vivebio Scientific, developer of a proprietary
vertical flow dried plasma separation device that enables high volume viral load testing, lipid panels and mass spectrometry. Prior to
Vivebio, Mr. Alecxih served as Chief Commercial Officer at ViewRay, where he managed global sales, marketing, and training for an early-stage
company in radiation oncology. Mr. Alecxih also spent 14 years at Intuitive Surgical, a
global technology leader in minimally invasive care and the pioneer of the da Vinci® robotic-assisted surgery system, where
he last served as Senior Vice President of Sales for North America, South America, Australia and New Zealand. At Intuitive
Surgical, Jim was integral in driving sales from $9 million annually to more than $1.8 billion annually and coordinated
the overall marketing strategy through four product launches and domestic and international expansion.
Earlier in his career, Mr. Alecxih held a variety of sales management roles at Johnson & Johnson's Ethicon Endo-Surgery. He holds a Bachelor of Arts degree in Business from Le Tourneau University in, Longview Texas.
About Applied UV
Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen’s Airocide® products for air purification, developed for NASA and FDA Cleared as class II medical devices, utilize a proprietary photo-catalytic bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous pathogens, destructive VOCs and biological gasses into harmless water vapor without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, and homes.
For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; and, https://munnworks.com/.
Forward-Looking Statements
The information contained herein may contain “forward-looking statements.” Forward-looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward-looking statements are based on the Company’s current expectations and assumptions regarding its business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company’s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Contact:
Applied UV Investor Relations
Kevin McGrath
TraDigital IR
+1-646-418-7002
kevin@tradigitalir.com